Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CBO 421

Next Previous
Drug Profile

CBO 421

Alternative Names: CBO-212; CBO-421; CD-421

Latest Information Update: 08 Jan 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cidara Therapeutics
  • Developer Merck & Co
  • Class Antineoplastics; Drug conjugates; Immunoconjugates; Immunoglobulin Fc fragments
  • Mechanism of Action 5-nucleotidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Solid tumours

Most Recent Events

  • 07 Jan 2026 Cidara Therapeutics has been acquired and merged into Merck & Co
  • 31 Jul 2024 US FDA approves IND application for CBO 421 in Solid tumours
  • 22 Apr 2024 Cidara Therapeutics plans to file an IND application for Solid tumours in mid-2024

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top